August 27, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on PharmAla Biotech Holdings, Inc. (CSE:MDMA/OTC:MDXXF) titled, “Monetizing Regulatory Advantage Through IP and Data”. The report can be accessed here.
PharmAla Biotech Holdings, Inc. (CSE: MDMA/OTCQB: MDXXF) is a Toronto-based biotech focused on developing, manufacturing, and commercializing MDMA and novel MDXX compounds for mental health and neurological disorders. Founded in 2020 by CEO Nick Kadysh, the company operates under a Health Canada Controlled Drugs and Substances Dealer’s License and has built an integrated cGMP MDMA supply chain spanning API manufacturing and drug product formulation.
Its business has two core segments. The first is a commercial MDMA supply operation focused on its LaNeo™ cGMP MDMA brand. PharmAla supplies the legal Australian prescription market through its Cortexa JV, supports clinical trials in the US, and provides clinical research material in Europe, generating modest but growing revenue.
The second segment is drug development. Lead candidate ALA-002, an MDMA-derived compound designed to reduce cardiovascular side effects, is expected to enter clinical testing in 2026. APA-01 is a preclinical program targeting stroke recovery and traumatic brain injury. PharmAla has adopted a capital-efficient strategy, out-licensing US rights to ALA-002 while retaining ex-US rights and preserving flexibility for APA-01 through potential internal development, partnerships, or future licensing. Supporting its pipeline is Phenesafe.AI, an AI-powered platform used to identify and prioritize novel MDXX compounds.
PharmAla combines a commercial MDMA supply business, a clinical-stage pipeline, and an emerging IP platform. From a valuation perspective, we benchmark it against companies involved in controlled-substance manufacturing, psychedelic and neuroplastogen drug development, and IP-driven licensing models to reflect its supply operations, proprietary CNS assets, and long-term value creation potential. While still early stage, PharmAla’s LaNeo platform, ALA-002 and APA-01 programs, and Phenesafe.AI discovery engine provide the foundation for a differentiated controlled-substance IP franchise.
About WTR. Modernizing Investor Engagement Through Research-Driven Strategies. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor engagement platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is open for everyone to access and distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients’ businesses, industries, and the investment opportunities they present.
